National Institutes of Health to Grant Exclusive License for Ovarian Cancer Treatment

Summary

The National Institutes of Health is considering granting an exclusive worldwide license to NeoPharm, Inc. for the therapeutic treatment of ovarian cancer and mesotheliomas, covering U.S. Patent Applications 08/776,271 and 60/067,175, and the SS(dsFv)-PE38 immunotoxin.